cAMP-specific 3',5'-cyclic phosphodiesterase 4B (PDE4B1) (PDE4B1)

cAMP-specific 3',5'-cyclic phosphodiesterase 4B (PDE4B) is a key enzyme that regulates intracellular signaling by hydrolyzing cyclic adenosine monophosphate (cAMP) into 5'-AMP (UniProt Q07343) [1]. The PDE4B1 isoform is one of several splice variants (including B2, B3, and B4) that differ in their N-terminal sequences, which facilitate specific protein-protein interactions and subcellular targeting (Biochemical Journal, 2005) [3]. This enzyme is predominantly expressed in immune cells and the central nervous system, where it plays a pivotal role in modulating inflammatory cascades and neurotransmission (NCBI Gene 5142) [2]. In inflammatory diseases like chronic obstructive pulmonary disease (COPD) and psoriasis, PDE4B is a primary driver of pro-inflammatory cytokine production, such as TNF-alpha and IL-12 (DrugBank DB06173) [4]. Furthermore, PDE4B has been identified as a risk factor for psychiatric disorders, including schizophrenia, due to its interaction with the DISC1 protein (Science, 2005) [5]. Therapeutic agents like roflumilast and apremilast target PDE4B to increase cAMP levels, thereby exerting anti-inflammatory effects, though their clinical utility is often hampered by gastrointestinal side effects like nausea and emesis (PubMed, 2014) [6].

Other names

PDE4BDPDE4PDEIVBcAMP-specific 3',5'-cyclic phosphodiesterase 4B

Competitive inhibition of the phosphodiesterase enzyme, preventing the hydrolysis of cAMP to 5'-AMP, thereby maintaining elevated cAMP levels which activate protein kinase A (PKA) and inhibit inflammatory signaling pathways.